1
项与 Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) 相关的临床试验Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies
CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.
100 项与 Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) 相关的临床结果
100 项与 Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) 相关的转化医学
100 项与 Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) 相关的专利(医药)
100 项与 Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) 相关的药物交易